Advanced

Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus.

Hillman, Magnus LU ; Eriksson, Leif LU ; Mared, Lena LU ; Helgesson, Karin and Landin-Olsson, Mona LU (2012) In Journal of Cystic Fibrosis 11(2). p.144-149
Abstract
Glucagon like peptide 1 (GLP-1) is an incretin hormone released as a bioactive peptide from intestinal L-cells in response to eating. It acts on target cells and exerts several functions as stimulating insulin and inhibiting glucagon. It is quickly deactivated by the serine protease dipeptidyl peptidase IV (DPP-IV) as an important regulatory mechanism. GLP-1 analogues are used as antidiabetic drugs in patients with type 2 diabetes. We served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23g protein, 25g fat and 76g carbohydrates) after an overnight fasting. Blood samples were collected before meal as well as 15, 30, 45 and 60min after the meal... (More)
Glucagon like peptide 1 (GLP-1) is an incretin hormone released as a bioactive peptide from intestinal L-cells in response to eating. It acts on target cells and exerts several functions as stimulating insulin and inhibiting glucagon. It is quickly deactivated by the serine protease dipeptidyl peptidase IV (DPP-IV) as an important regulatory mechanism. GLP-1 analogues are used as antidiabetic drugs in patients with type 2 diabetes. We served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23g protein, 25g fat and 76g carbohydrates) after an overnight fasting. Blood samples were collected before meal as well as 15, 30, 45 and 60min after the meal in tubes prefilled with a DPP-IV inhibitor. The aim of the study was to compare levels of GLP-1 in patients with CF, CFRD and in healthy controls. We found that active GLP-1 was significantly decreased in patients with CF and CFRD compared to in healthy controls (p<0.01). However, levels in patients with CFRD tended to be lower but were not significantly lower than in patients with CF without diabetes (p=0.06). Total GLP-1 did not differ between the groups, which points to that the inactive form of GLP-1 is more pronounced in CF patients. The endogenous insulin production (measured by C-peptide) was significantly lower in patients with CFRD as expected. However, levels in non-diabetic CF patients did not differ from the controls. We suggest that the decreased levels of GLP-1 could affect the progression toward CFRD and that more studies need to be performed in order to evaluate a possible treatment with GLP-1 analogues in CF-patients. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Cystic Fibrosis
volume
11
issue
2
pages
144 - 149
publisher
Elsevier
external identifiers
  • wos:000302423300011
  • pmid:22138561
  • scopus:84858286198
ISSN
1873-5010
DOI
10.1016/j.jcf.2011.11.001
language
English
LU publication?
yes
id
0c19736b-f0e0-49fd-a91d-1da95ffbdd3d (old id 2274603)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22138561?dopt=Abstract
date added to LUP
2012-01-02 13:18:25
date last changed
2017-11-19 03:21:53
@article{0c19736b-f0e0-49fd-a91d-1da95ffbdd3d,
  abstract     = {Glucagon like peptide 1 (GLP-1) is an incretin hormone released as a bioactive peptide from intestinal L-cells in response to eating. It acts on target cells and exerts several functions as stimulating insulin and inhibiting glucagon. It is quickly deactivated by the serine protease dipeptidyl peptidase IV (DPP-IV) as an important regulatory mechanism. GLP-1 analogues are used as antidiabetic drugs in patients with type 2 diabetes. We served patients with cystic fibrosis (CF, n=29), cystic fibrosis related diabetes (CFRD, n=19) and healthy controls (n=18) a standardized breakfast (23g protein, 25g fat and 76g carbohydrates) after an overnight fasting. Blood samples were collected before meal as well as 15, 30, 45 and 60min after the meal in tubes prefilled with a DPP-IV inhibitor. The aim of the study was to compare levels of GLP-1 in patients with CF, CFRD and in healthy controls. We found that active GLP-1 was significantly decreased in patients with CF and CFRD compared to in healthy controls (p&lt;0.01). However, levels in patients with CFRD tended to be lower but were not significantly lower than in patients with CF without diabetes (p=0.06). Total GLP-1 did not differ between the groups, which points to that the inactive form of GLP-1 is more pronounced in CF patients. The endogenous insulin production (measured by C-peptide) was significantly lower in patients with CFRD as expected. However, levels in non-diabetic CF patients did not differ from the controls. We suggest that the decreased levels of GLP-1 could affect the progression toward CFRD and that more studies need to be performed in order to evaluate a possible treatment with GLP-1 analogues in CF-patients.},
  author       = {Hillman, Magnus and Eriksson, Leif and Mared, Lena and Helgesson, Karin and Landin-Olsson, Mona},
  issn         = {1873-5010},
  language     = {eng},
  number       = {2},
  pages        = {144--149},
  publisher    = {Elsevier},
  series       = {Journal of Cystic Fibrosis},
  title        = {Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus.},
  url          = {http://dx.doi.org/10.1016/j.jcf.2011.11.001},
  volume       = {11},
  year         = {2012},
}